The research team, led by Miriam T. Y. Leung of Monash University in collaboration with colleagues at the University of Eastern Finland, drew on the FINPARK cohort, a nationwide register-based dataset covering the entire Finnish population. The study included 11,051 people diagnosed with Parkinson’s disease between 2000 and 2009, each matched by age and sex to two comparison individuals without the disease, yielding 22,102 matched controls. By linking records from the Care Register for Healthcare, the Prescription Register, and Statistics Finland through each resident’s unique personal identification number, the researchers could track every dispensing of anti-osteoporosis medication, every hospital admission, and every death across an extraordinary fifteen-year window: five years before the Parkinson’s diagnosis and ten years after it.

The medications under scrutiny were the standard pharmacological arsenal against osteoporosis: bisphosphonates, the workhorse antiresorptive drugs that slow bone breakdown; denosumab, a monoclonal antibody that blocks the cells responsible for bone resorption; and calcitonin, an older hormone-based therapy that has largely fallen out of favor and was withdrawn from the Finnish market in 2012 due to limited efficacy. Annual prevalence was calculated as the proportion of cohort members who received at least one dispensing of any of these drugs in a given year, restricted to people who spent at least sixty days living in the community to allow realistic opportunity for pharmacy dispensing.

The first major finding was unexpected. Contrary to earlier reports suggesting that osteoporosis is chronically under-recognized in people with Parkinson’s, the Finnish data showed that medication use was actually higher among people with the disease than among matched controls. The divergence emerged surprisingly early, three full years before the formal diagnosis of Parkinson’s, when 3.62 percent of people who would later be diagnosed were receiving anti-osteoporosis therapy compared with 2.91 percent of controls. That gap widened dramatically after diagnosis, peaking four years in, when 8.67 percent of the Parkinson’s group were being treated versus just 4.73 percent of the comparison group, and it remained elevated through the end of follow-up.

Why would bone-protecting drugs appear in the records of people three years before anyone has diagnosed their Parkinson’s? The authors point to the prodromal phase of the disease, the period when early motor and non-motor symptoms, including subtle balance problems and increased fall risk, begin to manifest before the classic diagnostic criteria are met. Their own previous work in the same cohort showed that hip fracture risk is already elevated in the years preceding diagnosis. Fractures themselves may also act as a trigger: a person who breaks a bone is more likely to be screened for osteoporosis and started on treatment, and the heightened dispensing observed after hip fractures in this study supports exactly that pathway. Reduced mobility and greater use of psychotropic medications, both documented in this cohort years before diagnosis, further compound the fracture risk.

The second key finding concerns what happens after a hip fracture, the moment when secondary prevention matters most. Among the 1,475 people with Parkinson’s and 1,371 controls who suffered an incident hip fracture during follow-up, treatment patterns were strikingly similar between the two groups. Anti-osteoporosis dispensing peaked within the first year after the fracture, reaching 20.3 percent in the Parkinson’s group and 21.0 percent in the controls, roughly one in five patients. By five years after the fracture, prevalence had settled to around 14 to 16 percent in both groups. In other words, having Parkinson’s neither helped nor hindered access to post-fracture pharmacological prevention, a result that directly contradicts the under-treatment narrative from smaller earlier studies.

Yet the absolute numbers tell a more sobering story. A one-in-five treatment rate after a fragility fracture leaves four in five patients without the therapy that could prevent the next break, and the Finnish figures, while comparable to other Nordic countries, fall far short of the more than 50 percent post-fracture treatment prevalence reported in the United Kingdom. The authors attribute part of this gap to national guideline differences. The Finnish Current Care Guideline on hip fracture recommends anti-osteoporosis medications only for patients expected to regain independent mobility, explicitly excluding those anticipated to remain bedbound, and it places heavy emphasis on fall-risk management, noting that ninety percent of hip fractures result from a fall. Multidisciplinary fracture liaison services, which systematically assess every fracture patient, have been shown elsewhere to raise both treatment rates and fall-prevention efforts, and the study suggests they could play a valuable role in Finland.

Sex differences added another layer of complexity. Women, whether with or without Parkinson’s, received anti-osteoporosis medications at consistently higher rates than men throughout follow-up, reflecting the earlier onset of postmenopausal bone loss. Among women with Parkinson’s, treatment prevalence peaked at 15.5 percent four years after diagnosis, then declined, a pattern consistent with postmenopausal osteoporosis being treated early and later paused. Men with Parkinson’s showed the opposite trajectory, with use climbing slowly to a peak of just 3.16 percent eight years after diagnosis. After hip fracture, women again led with 25.6 percent treated within a year versus 12.2 percent of men, but men’s post-fracture treatment remained elevated for up to five years while women’s declined. The gradual decline in bisphosphonate use beyond four years after diagnosis may reflect not only poor adherence, a well-documented problem with oral bisphosphonates, but also deliberate clinical decisions: guidelines recommend a drug holiday of one to two years after three to five years of bisphosphonate therapy in lower-risk patients to minimize long-term adverse effects.

The study’s strengths lie in its scale and completeness. Nationwide registers minimize selection bias, the fifteen-year follow-up captures the full arc from prodrome to late disease, and the prediagnostic window, never examined before in this context, proved scientifically critical given that fracture risk is already elevated before diagnosis. The limitations are equally instructive: over-the-counter vitamin D and calcium, dispensed without prescription, were invisible to the database; no bone mineral density measurements or blood tests were available to judge whether treatment matched individual bone health; and medications administered intravenously in hospitals, such as zoledronic acid, could not be captured. These gaps mean the true extent of bone-protective care may be somewhat higher than the dispensing records suggest.

The takeaway for clinicians and researchers is that the problem in Parkinson’s may not be unequal access to osteoporosis drugs, but rather that drugs alone are not enough to counteract a risk that is doubled at its source. With sustained fracture risk extending a full decade after diagnosis, the authors argue that additional preventive measures, above all regular and systematic review of fall risk, must run alongside pharmacotherapy. As Parkinson’s prevalence continues its steep global climb, protecting the skeletons of the people it affects may demand a shift from reactive treatment after the break to proactive, multidisciplinary prevention before the fall ever happens.

Subject of Research: Anti-osteoporosis medication use in persons with and without Parkinson's disease in Finland

Article Title: Anti-osteoporosis medications in persons with and without Parkinson disease in Finland

Article References: Leung, M. T. Y., Lamidi, M.-L., Tiihonen, M., Hartikainen, S., Bell, J. S., Turner, J. P., & Tolppanen, A.-M. (2026). Anti-osteoporosis medications in persons with and without Parkinson disease in Finland. Archives of Osteoporosis, 21(1), Article 143. https://doi.org/10.1007/s11657-026-01780-z

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01780-z

Keywords: Parkinson's disease, osteoporosis, hip fracture, bisphosphonates, denosumab, anti-osteoporosis medications, Finland, nationwide cohort, fracture prevention, fall risk, secondary prevention, bone health

The research team, led by investigators at Samsung Medical Center in Seoul, drew on the Korean Nationwide Cancer Public Library Database, a national registry that links cancer diagnoses with prescription records, hospital visits, and death certificates. From this resource they identified 14,736 women newly diagnosed with ovarian or fallopian tube cancer between 2012 and 2019. Because South Korea’s National Health Insurance Service covers virtually the entire population, the database captures an unusually complete picture of real-world medication use, avoiding the recall bias that plagues studies asking patients to remember what they took years earlier.

The investigators classified NSAID exposure in two complementary ways. First, they looked at timing relative to diagnosis: women who filled NSAID prescriptions only within the six months after diagnosis were labeled POST users, while those who used the drugs both before and after diagnosis were labeled PRE and POST users. Second, they measured frequency of use after diagnosis, dividing patients into low users who took NSAIDs less than one day per week, intermediate users taking one to three days per week, and high users taking four or more days per week. This dual classification allowed the team to distinguish whether sustained use around the diagnostic window mattered more than intensity of use afterward.

The biological rationale for the study rests on decades of evidence that inflammation is not merely a symptom of cancer but an active participant in its progression. NSAIDs block cyclooxygenase enzymes, known as COX-1 and COX-2, which convert arachidonic acid into prostaglandins such as prostaglandin E2. In the ovarian tumor microenvironment, prostaglandin E2 has been linked to immune suppression, angiogenesis through vascular endothelial growth factor signaling, and the recruitment of myeloid-derived suppressor cells, all of which can blunt the body’s antitumor defenses and undermine chemotherapy. By dampening these pathways, NSAIDs have shown anticancer effects in other malignancies, including head and neck squamous cell carcinoma, prompting researchers to ask whether the same logic applies to ovarian cancer, a disease notoriously resistant to treatment in its advanced stages.

Over a median follow-up of 2.91 years, 4,108 of the women in the study died, a mortality rate of 27.9 percent. The team used Cox proportional hazards models, the standard statistical framework for survival analysis, adjusting for demographic characteristics, comorbidities measured by the Charlson Comorbidity Index, cancer stage, and treatment-related factors. The results were sobering for those hoping for a simple answer. In the fully adjusted model of the overall cohort, neither the timing of NSAID use nor the frequency of use after diagnosis was significantly associated with all-cause mortality. Women who used NSAIDs both before and after diagnosis had a hazard ratio of 0.94, with a 95 percent confidence interval of 0.88 to 1.01, a range that just crosses the threshold of statistical significance. High-frequency users fared similarly, with a hazard ratio of 0.92 and a confidence interval of 0.82 to 1.04.

But the story changed dramatically when the researchers stratified the cohort by initial treatment sequence, splitting patients into those who received surgery first and those who began with chemotherapy. Among women in the surgery-first group, the associations turned significant. Those who used NSAIDs both before and after diagnosis had a hazard ratio of 0.89, with a confidence interval of 0.82 to 0.97, indicating an eleven percent lower risk of death compared with women who did not. High-frequency users in this subgroup showed an even stronger signal, with a hazard ratio of 0.84 and a confidence interval of 0.73 to 0.98. In the chemotherapy-first subgroup, by contrast, no associations were found at all, regardless of timing or frequency.

Why might surgery-first patients benefit while chemotherapy-first patients show no effect? The authors and observers point to several plausible mechanisms. Surgery itself triggers a profound inflammatory response, releasing cytokines such as tumor necrosis factor-alpha and interleukin-8, and perioperative inflammation is known to suppress tumor-infiltrating lymphocytes, the immune cells that correlate with better outcomes in ovarian cancer. NSAIDs taken around the time of surgery could theoretically blunt this inflammatory surge and preserve antitumor immunity. Patients undergoing chemotherapy first, often those with more advanced or inoperable disease, may represent a biologically different population in which the dominant drivers of mortality are tumor aggressiveness rather than treatment-related inflammation, leaving less room for NSAIDs to matter.

The researchers themselves urge caution, and their language is deliberately restrained. They note that the significant findings in the surgery-first subgroup require cautious interpretation given multiple potential sources of residual confounding. Observational studies of this kind cannot prove causation, and the very fact that NSAID use was associated with benefit in one subgroup but not another raises the possibility of confounding by indication or by underlying health status. Women well enough to undergo primary surgery tend to have earlier-stage disease, better performance status, and different comorbidity profiles than those routed directly to chemotherapy, and even sophisticated statistical adjustment cannot fully erase these differences. Reverse causation is another concern: women with advanced disease may avoid NSAIDs or be prescribed them differently, distorting the apparent relationship between the drugs and survival.

There are also technical limitations inherent to prescription-database research. Over-the-counter NSAID purchases may not be fully captured, meaning some exposure could be misclassified. The study measured all-cause mortality rather than cancer-specific mortality, so deaths from cardiovascular events or other causes dilute any drug-specific signal. The dose and duration of NSAID use were approximated from prescription frequency rather than actual consumption, and the analysis could not distinguish reliably among individual agents, from non-selective NSAIDs such as ibuprofen and naproxen to selective COX-2 inhibitors, each with distinct pharmacology and safety profiles. Supplementary analyses by SEER stage, extent of surgical procedure, and intensive care unit admission were performed to probe the robustness of the findings, but no observational design can eliminate uncertainty entirely.

Still, the scale of the study gives its null and subgroup findings real weight. With nearly fifteen thousand patients drawn from a single-payer national system, this is among the largest investigations of peri-diagnostic NSAID use in ovarian cancer to date, and one of the first in an Asian population, where prior evidence has been sparse. The authors, who declare no competing interests and received no specific funding for the work, emphasize that their results do not support recommending NSAIDs to ovarian cancer patients as a survival intervention. Instead, the surgery-first signal should be viewed as a hypothesis generator, pointing toward randomized or mechanistic studies that could test whether perioperative anti-inflammatory treatment genuinely alters the tumor microenvironment and improves outcomes. Until such evidence arrives, the humble painkillers in nearly every medicine cabinet remain exactly what they have always been for ovarian cancer patients: useful for pain, unproven for survival, and now the subject of a tantalizing question that only further research can answer.

Subject of Research: Peri-diagnostic NSAID use and all-cause mortality in ovarian cancer

Article Title: Peri-diagnostic NSAID use and all-cause mortality in ovarian cancer: nationwide cohort study

Article References: Peri-diagnostic NSAID use and all-cause mortality in ovarian cancer: nationwide cohort study. (n.d.). https://doi.org/10.1186/s13048-026-02278-5

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02278-5

Keywords: ovarian cancer, NSAIDs, all-cause mortality, nationwide cohort, inflammation, COX-2, tumor microenvironment, surgery-first, chemotherapy-first, Korea, survival analysis, epidemiology